APPLY

2025

Winner of the €100,000 Jorge Ruas Award

AAV-Based Gene Therapy for PPMS

AAV-Based Gene Therapy for PPMS is an innovative gene therapy approach for Primary Progressive Multiple Sclerosis (PPMS), a severe form of multiple sclerosis that causes progressive and irreversible neurological damage.

The project is designed to overcome one of the major challenges in treating diseases of the brain: delivering therapies across the blood-brain barrier.

Using an AAV9-based delivery system, the therapy enables cells in the central nervous system to produce Interleukin-2 (IL-2) locally, with the aim of reducing inflammation and supporting repair. Preclinical studies in mouse models demonstrated significant attenuation of disease progression.

The Team

James Dooley
Joana Paes de Faria Monteiro
Matthew Holt

Organisation: Aila Biotech